Compare LMNR & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMNR | CABA |
|---|---|---|
| Founded | 1893 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 256.6M | 212.7M |
| IPO Year | 2005 | 2019 |
| Metric | LMNR | CABA |
|---|---|---|
| Price | $14.25 | $3.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $20.00 | $14.57 |
| AVG Volume (30 Days) | 39.6K | ★ 2.7M |
| Earning Date | 03-26-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.12% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $159,723,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.99 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.20 | $0.99 |
| 52 Week High | $22.85 | $3.67 |
| Indicator | LMNR | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 49.61 | 71.51 |
| Support Level | $13.93 | $2.11 |
| Resistance Level | $14.93 | N/A |
| Average True Range (ATR) | 0.35 | 0.26 |
| MACD | -0.04 | 0.07 |
| Stochastic Oscillator | 34.09 | 98.94 |
Limoneira Co is predominantly an agribusiness company. Its current operations consist of fruit production and marketing, rental operations, real estate, and capital investment activities. The company has three business divisions; agribusiness, rental operations, and real estate development. The agribusiness division which accounts for a majority of the firm's revenue represents its core operations of farming, harvesting, lemon packing, and lemon sales operations. The company's reportable operating segments are fresh lemons, lemon packing, avocados, and other agribusiness, which predominantly includes oranges, specialty citrus, other crops, and farm management services. A majority of its revenue is derived from the Fresh Lemons segment.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.